Zomedica Corp. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Zomedica Corp. (ZOMDF) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$1.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-05
- Zomedica Corp. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $365.00K, a 79.24% decline year-over-year.
- Zomedica Corp. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $1.76M.
- Zomedica Corp. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$1.97M.
- Zomedica Corp. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$19.05M.
- Zomedica Corp. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $1.93M.
- Zomedica Corp. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$5.85M.
- Zomedica Corp. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$14.40M.
- Zomedica Corp. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$167.54M, a 226.01% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.80M 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $365.00K 10-Q · filed 2026-05-06 | |||
| 2025-12-31 | $1.93M 10-K · filed 2026-03-16 | |||
| 2025-09-30 | $376.00K 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $995.00K 10-Q · filed 2026-08-05 | |||
| 2025-03-31 | $1.76M 10-Q · filed 2026-05-06 | |||
| 2024-12-31 | -$5.85M 10-K · filed 2026-03-16 | |||
| 2024-09-30 | -$3.24M 10-Q · filed 2025-11-04 | |||
| 2024-06-30 | -$4.91M 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | -$1.97M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | -$14.40M 10-K · filed 2025-03-13 | |||
| 2023-09-30 | -$5.55M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $596.00K 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | -$19.05M 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | -$167.54M 10-K · filed 2024-04-01 | |||
| 2022-09-30 | -$149.81M 10-Q · filed 2023-11-13 | |||
| 2022-06-30 | -$8.16M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | -$2.68M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $132.96M 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $209.42M 10-Q · filed 2022-11-14 |